Search Results - "Shuldiner, A. R"

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 ( ) Genotype and Clopidogrel Therapy by Scott, SA, Sangkuhl, K, Gardner, EE, Stein, CM, Hulot, J‐S, Johnson, JA, Roden, DM, Klein, TE, Shuldiner, AR

“…CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19*2…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update by Scott, S A, Sangkuhl, K, Stein, C M, Hulot, J-S, Mega, J L, Roden, D M, Klein, T E, Sabatine, M S, Johnson, J A, Shuldiner, A R

“…Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active…”
Get full text

Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes by Lin, P.I, Shuldiner, A.R

“…Abstract The co-occurrence of schizophrenia (SCZ) and type 2 diabetes mellitus (T2D) has been well documented. This review article focuses on the hypothesis…”
Get full text

Clopidogrel pharmacogenetics: Beyond candidate genes and genome‐wide association studies by Lewis, JP, Shuldiner, AR

“…While it is well established that genetic variation is a significant contributor to interindividual variability in clopidogrel efficacy, candidate gene and…”
Get full text

Clopidogrel: A Case for Indication-Specific Pharmacogenetics by Johnson, J A, Roden, D M, Lesko, L J, Ashley, E, Klein, T E, Shuldiner, A R

“…The CYP2C19*2 loss‐of‐function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta‐analyses have supported or…”
Get full text

Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions by Beitelshees, AL, Horenstein, RB, Vesely, MR, Mehra, MR, Shuldiner, AR

“…A 62‐year‐old presents with angina. He has been genotyped for a panel of drug metabolism enzymes through a direct‐to‐consumer genetics company. His results…”
Get full text

The CYP2C1917 variant is not independently associated with clopidogrel response by Lewis, J. P., Stephens, S. H., Horenstein, R. B., O'Connell, J. R., Ryan, K., Peer, C. J., Figg, W. D., Spencer, S. D., Pacanowski, M. A., Mitchell, B. D., Shuldiner, A. R.

“…Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme responsible for converting clopidogrel into its active metabolite, and common genetic…”
Get full text

Educational innovations in clinical pharmacogenomics by Perry, CG, Maloney, KA, Beitelshees, AL, Jeng, LJB, Ambulos Jr, NP, Shuldiner, AR, Blitzer, MG

“…Genetic and genomic discovery is revolutionizing medicine at an extraordinary pace, leading to a better understanding of disease and improved treatments for…”
Get full text

Paraoxonase 1 ( ) Gene Variants Are Not Associated With Clopidogrel Response by Lewis, J P, Fisch, A S, Ryan, K, O'Connell, J R, Gibson, Q, Mitchell, B D, Shen, H, Tanner, K, Horenstein, R B, Pakzy, R, Tantry, U S, Bliden, K P, Gurbel, P A, Shuldiner, A R

“…A common functional variant in paraoxonase 1 (PON1), Q192R, was recently reported to be a major determinant of clopidogrel response. This variant was genotyped…”
Get full text

Identifying clinically relevant sources of variability: The clopidogrel challenge by Samant, S, Jiang, XL, Peletier, LA, Shuldiner, AR, Horenstein, RB, Lewis, JP, Lesko, LJ, Schmidt, S

“…High interindividual variability in clinical outcomes following clopidogrel's standard dosing regimen continues to be a challenge even two decades after its…”
Get full text

Pharmacogenomics: Application to the Management of Cardiovascular Disease by Johnson, J A, Cavallari, L H, Beitelshees, A L, Lewis, J P, Shuldiner, A R, Roden, D M

“…The past decade has seen substantial advances in cardiovascular pharmacogenomics. Genetic determinants of response to clopidogrel and warfarin have been…”
Get full text

The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response by Giacomini, K M, Brett, C M, Altman, R B, Benowitz, N L, Dolan, M E, Flockhart, D A, Johnson, J A, Hayes, D F, Klein, T, Krauss, R M, Kroetz, D L, McLeod, H L, Nguyen, A T, Ratain, M J, Relling, M V, Reus, V, Roden, D M, Schaefer, C A, Shuldiner, A R, Skaar, T, Tantisira, K, Tyndale, R F, Wang, L, Weinshilboum, R M, Weiss, S T, Zineh, I

“…The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to…”
Get full text

CPT1A methylation is associated with plasma adiponectin by Aslibekyan, S, Do, A.N, Xu, H, Li, S, Irvin, M.R, Zhi, D, Tiwari, H.K, Absher, D.M, Shuldiner, A.R, Zhang, T, Chen, W, Tanner, K, Hong, C, Mitchell, B.D, Berenson, G, Arnett, D.K

“…Abstract Background and aims Adiponectin, an adipose-secreted protein that has been linked to insulin sensitivity, plasma lipids, and inflammatory patterns, is…”
Get full text

Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes by Clement, K, Hercberg, S, Passinge, B, Galan, P, Varroud-Vial, M, Shuldiner, A.R, Beamer, B.A, Charpentier, G, Guy-Grand, B, Froguel, P

“…OBJECTIVE: Peroxisome-proliferator-activated receptors gamma (PPAR gamma), is a key regulator of adipocyte differentiation and energy balance. Two naturally…”
Get full text

Pharmacometabolomics Reveals That Serotonin Is Implicated in Aspirin Response Variability by Ellero‐Simatos, S, Lewis, JP, Georgiades, A, Yerges‐Armstrong, LM, Beitelshees, AL, Horenstein, RB, Dane, A, Harms, AC, Ramaker, R, Vreeken, RJ, Perry, CG, Zhu, H, Sànchez, CL, Kuhn, C, Ortel, TL, Shuldiner, AR, Hankemeier, T, Kaddurah‐Daouk, R

“…While aspirin is generally effective for prevention of cardiovascular disease, considerable variation in drug response exists, resulting in some individuals…”
Get full text

Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study by HSUEH, W.-C, MITCHELL, B. D, BURNS, D. K, BELL, C. J, SHULDINER, A. R, ABUROMIA, R, POLLIN, T, SAKUL, H, EHM, M. G, MICHELSEN, B. K, WAGNER, M. J, JEAN, P. L. S, KNOWLER, W. C

“…Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study. W C Hsueh , B D Mitchell , R Aburomia , T…”
Get full text

Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study by LEI, H.-H, CORESH, J, SHULDINER, A. R, BOERWINKLE, E, BRANCATI, F. L

“…Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in…”
Get full text

Association Between Uncoupling Protein Polymorphisms (UCP2–UCP3) and Energy Metabolism/Obesity in Pima Indians by Walder, Ken, Norman, Rod A., Hanson, Robert L., Schrauwen, Patrick, Neverova, Maria, Jenkinson, Chris P., Easlick, Juliet, Warden, Craig H., Pecqueur, Claire, Raimbault, Serge, Ricquier, Daniel, Harper, Michael, Silver, Kristi, Shuldiner, Alan R., Solanes, Gemma, Lowell, Bradford B., Chung, Wendy K., Leibel, Rudolph L., Pratley, Richard, Ravussin, Eric

“…The UCP2–UCP3 gene cluster maps to chromosome 11q13 in humans, and polymorphisms in these genes may contribute to obesity through effects on energy metabolism…”
Get full text

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation by Shuldiner, A R, Relling, M V, Peterson, J F, Hicks, K, Freimuth, R R, Sadee, W, Pereira, N L, Roden, D M, Johnson, J A, Klein, T E

“…The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new…”
Get full text

Searching for human longevity genes: the future history of gerontology in the post-genomic era by Barzilai, N, Shuldiner, A R

“…Over the last 30 years, a number of genetic and environmental factors that lead to decreased length of life have been identified. Unfortunately, much less…”
Get full text